Hnscc

The 1975 - HNSCC

Immunotherapy in HNSCC

Surgery for Locally Advanced HNSCC

Dr Kirtane on an Investigation of TILs Plus Pembrolizumab in Advanced HNSCC

CDKN2A and TP53 mutation in HPV-negative HNSCC

Phase II trial of pembrolizumab and cabozantinib in HNSCC

Biology of Head and Neck Squamous Cell Cancer (HNSCC)

LIONESS: a personalized cell-free tumor DNA analysis for patients with HNSCC.

Dr Sun on Tisotumab Vedotin in Recurrent or Metastatic HNSCC

Phase II study of petosemtamab and pembrolizumab for recurrent/metastatic HNSCC

Immunotherapy for Recurrent HNSCC

Mono or combination immunotherapy for HNSCC?

The Role of Induction Chemotherapy in HNSCC

De-Escalation of Therapy for HPV-Positive HNSCC

Petosemtamab has promising activity in advanced HNSCC

Comparing petosemtamab and pembrolizumab in HNSCC with existing therapies

Clinical Trial Endpoint for Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

U.S. Food and Drug Administration

KEYNOTE-048: pembrolizumab monotherapy for frontline R/M HNSCC

DEPEND: nivolumab with chemotherapy and response-stratified CRT in HNSCC